{"title":"左心室重构的药物治疗:最近的试验结果","authors":"A. Tomasik, E. Nowalany-Kozielska","doi":"10.4155/CLI.15.44","DOIUrl":null,"url":null,"abstract":"Ventricular remodeling, recently characterized as an inhomogeneous entity, has quickly become a therapeutic target. It is assumed that prevention of ventricle remodeling would stop the progression of heart failure. In this review we discuss briefly the issue of ventricular remodeling along with underlying mechanisms leading to cardiac hypertrophy and/or dilatation. Furthermore, we discuss the pharmacologic approaches to prevent left ventricle remodeling, either in animal studies or human trials.","PeriodicalId":10369,"journal":{"name":"Clinical investigation","volume":"23 1","pages":"767-776"},"PeriodicalIF":0.0000,"publicationDate":"2015-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Pharmacological treatment of left ventricular remodeling: recent trial results\",\"authors\":\"A. Tomasik, E. Nowalany-Kozielska\",\"doi\":\"10.4155/CLI.15.44\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Ventricular remodeling, recently characterized as an inhomogeneous entity, has quickly become a therapeutic target. It is assumed that prevention of ventricle remodeling would stop the progression of heart failure. In this review we discuss briefly the issue of ventricular remodeling along with underlying mechanisms leading to cardiac hypertrophy and/or dilatation. Furthermore, we discuss the pharmacologic approaches to prevent left ventricle remodeling, either in animal studies or human trials.\",\"PeriodicalId\":10369,\"journal\":{\"name\":\"Clinical investigation\",\"volume\":\"23 1\",\"pages\":\"767-776\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-10-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical investigation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4155/CLI.15.44\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4155/CLI.15.44","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Pharmacological treatment of left ventricular remodeling: recent trial results
Ventricular remodeling, recently characterized as an inhomogeneous entity, has quickly become a therapeutic target. It is assumed that prevention of ventricle remodeling would stop the progression of heart failure. In this review we discuss briefly the issue of ventricular remodeling along with underlying mechanisms leading to cardiac hypertrophy and/or dilatation. Furthermore, we discuss the pharmacologic approaches to prevent left ventricle remodeling, either in animal studies or human trials.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
